Corona Virus Vaccine
The Corona Virus is a highly contagious disease that can be spread through contact. It can also be transmitted to healthy persons by non-contagious means. This disease is highly fatal in humans and leads to extensive damage of organs, resulting in death. It is caused by a strains of a spirochete known as Q fever virus (Kepelikel-CVV) that apparently first surfaced decades ago in mountainous regions in the Andes. The disease is named after the town of Corona, Mendoza, in the central region of Colombia.
Corona Virus Vaccine was manufactured by Asiaone GlaxoSmithKline and marketed under several brands. The earliest version of Corona was designated as sars-cov-2, and later re-designated as coco-sars-cov-2. It is administered via an injection pump placed directly into the chest cavity. In most cases, this vaccine has shown better efficacy than live vaccines, despite lower titre and less thorough virucopacity screening.
Corona Virus vaccine has shown some improvement in efficacy and safety in children and adolescents. For adults, it is generally well tolerated and shows very low incidence of complications. Corona vaccine is a modified form of chadoxyl-transfective vaccine; therefore, the two differ only in the placer region of the envelope protein. Furthermore, unlike in chadoxyl-transfective vaccines, there is no requirement for a booster shot, although this may be necessary in some jurisdictions. Despite these differences, both are generally safe and effective, with some benefits for each category of population.
Recently, a phase II clinical trial comparing two different combination vaccines, called rVSV-zoster and HPV-8 vaccine showed that patients who received doses of Corona Virus vaccine showed significant reductions in the prevalence of herpes simplex virus (HSV) infection. The study also showed that patients who received the vaccine had lower odds of experiencing outbreaks that lasted for more than seven days. Another trial comparing two very similar vaccines (a live-virus vaccine and a injectable form of the vaccine) known as cuvirax and valaciclovir showed that patients who received doses of either vaccine showed a significant reduction in the development of interferon-induced prophylaxis (IFP). Compared to placebo, patients who received cuvirax and valaciclovirines had a significant lower rate of fever, fewer skin rash outbreaks, fewer laboratory infections, and lower viral titers. In addition, the combination showed an increased duration of viral shedding and absence of fever blisters.
A phase II clinical trial comparing two different vaccines, called valaciclovir (rivalrix) and valacyclovir (zacelan), was recently completed and reported results of the trial showing that both drugs significantly reduced the risk of contacting herpes disease. One of the vaccines in this combination was shown to have greater efficacy in women with meningitis. The clinical trial also demonstrated that recipients of the vaccine were protected from outbreaks when they had no underlying conditions of transmission. Compared to placebo, the women receiving valaciclovir had significantly fewer fever blisters and sore lesions.
Two Spanish regions-carabao and Cantabria-are currently administering aefi and valaciclovir vaccines. There is no information on the vaccine's safety profile in Spain. Recently, a study comparing aefi and valaciclovir in patients with chronic cerebellar ataxia and progressive cerebellar ataxia showed that the sars-cov-2 vaccine was not effective in these patients. A previous phase IIIb clinical trial comparing the two vaccines, s-cells and gene-expression plasmid p antis.r.t., showed that aefi was not more effective than the valaciclovir/placebo combination for reducing the virus shedding in people with acute florida and improving the symptoms of genital herpes infection. However, it is not known whether it was due to unavailability of the placebo in these settings.
https://sgnewssingapore.edublogs.org/2021/09/20/singapore-news-about-covid-vaccine/
https://straighttimesingapore.wordpress.com/2021/09/20/sports-news-in-singapore/
https://mqiu809.wixsite.com/straighttimesingapor/post/digital-culture-news-in-singapore
